BNTX240719C125000
- 0.05
- 0.000.00%
BioNTech Newsroom
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending higher late Wednesday morning, rising 0.6% to 1,436.74 on the S&P Europe Select ADR Index. From continental Europe, the
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
Wednesday, GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) announced they have restructured their existing collaboration into a new licensing agreement, allowing the companies to prioritize investme
Pfizer-BioNTech, Moderna Set to Appeal Mixed UK Ruling in COVID-19 Vaccine Patent Case
Moderna (0QF.F) and its rivals Pfizer (PFE.F) and BioNTech (22UA.F) are considering appeals after London's High Court handed down a mixed ruling in their patent dispute relating to the mRNA technology
Unusual Options Activity: WBD, BNTX and Others Attract Market Bets, WBD V/OI Ratio Reaches 921.1
EST Jul 1st Closing Delivery - In the last three hours of trading, 4 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Morgan Stanley Maintains BioNTech(BNTX.US) With Hold Rating, Maintains Target Price $101
Morgan Stanley analyst Terence Flynn maintains $BioNTech(BNTX.US)$ with a hold rating, and maintains the target price at $101.According to TipRanks data, the analyst has a success rate of 65.1% and a
Morgan Stanley Sticks to Its Hold Rating for BioNTech SE (BNTX)
Andreas & Thomas Struengmann Award Honors HAYA Therapeutics Co-founders as Inaugural Winners
The award jury selected Samir Ounzain, PhD and Daniel Blessing, PhD, the two co-founders of HAYA Therapeutics, as the winners from an outstanding finalist group of life science entrepreneurs Represe
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading
European equities traded in the US as American depositary receipts were moving slightly higher late Friday morning, rising 0.12% to 1,424.97 on the S&P Europe Select ADR Index. However, the gain likel
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
One graphic to understand | the June bull and bear stocklist of U.S. stocks is released! Optional consumer and technology sectors are performing strongly, Arm rose more than 38%, and Adobe rose nearly 23%.
The three major US stock indexes rose collectively this month, putting a perfect end to the first half of the year. Large-cap tech stocks continued their rally, driving the Nasdaq up by 6.71% this month, the best performer. The S&P 500 rose 3.89% this month and the Dow Jones rose 1.23%.
CHMP Recommends Authorisation for Pfizer-BioNTech's Covid-19 Vaccine
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
On Wednesday, the FDA approved Epkinly (epcoritamab-bysp) as the first and only T-cell-engaging bispecific antibody administered subcutaneously for adults with relapsed or refractory follicular lympho
Express News | Pfizer and BioNTech Receive Positive Chmp Opinion for Omicron Jn.1-Adapted Covid-19 Vaccine in the European Union
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older Recommendation is based on pre-clinical and epidemiological data
Evaluating BioNTech: Insights From 12 Financial Analysts
In the preceding three months, 12 analysts have released ratings for BioNTech (NASDAQ:BNTX), presenting a wide array of perspectives from bullish to bearish.The table below summarizes their recent rat
HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.
BioNTech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/26/2024 34.05% HC Wainwright & Co. $113 → $113 Reiterates Buy → Buy 06/10/2024 34.05% HC Wainwright & C
H.C. Wainwright Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $113
H.C. Wainwright analyst Robert Burns maintains $BioNTech(BNTX.US)$ with a buy rating, and maintains the target price at $113.According to TipRanks data, the analyst has a success rate of 24.0% and a t
Unusual Options Activity: PPL, JD and Others Attract Market Bets, PPL V/OI Ratio Reaches 89.4
EST Jun 24th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trend
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan